| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
31 |
| Employees |
72 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
3 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing cell therapies for various types of cancers and other serious diseases. The company utilizes its proprietary Controlled Switch Technology (CST) platform to engineer and control cellular therapies. Bellicum's CST platform allows for the activation and elimination of these cellular therapies to enhance safety and efficacy.
The company's lead product candidate, BPX-601, is a CAR-T cell therapy that is being developed for the treatment of pancreatic cancer. Bellicum also has a pipeline of other product candidates in various stages of development, targeting different types of cancers, including prostate and ovarian cancer.
In addition to cancer, Bellicum is exploring the potential of its CST platform for other therapeutic areas such as inherited blood disorders and autoimmune diseases. The company has collaborations with eminent research institutions and pharmaceutical companies to advance its technology and develop innovative treatments.
Bellicum Pharmaceuticals Inc is dedicated to improving patient outcomes through its cell therapy platform and continues to invest in research and development to bring new and effective treatments to market.
Company Address: 3730 Kirby Drive, Houston, 77098 TX
Company Phone Number: 454-3424 Stock Exchange / Ticker: BLCM
|
%
0.07%